1620450-59-0Relevant articles and documents
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms
Tong, Ling,Yu, Wensheng,Chen, Lei,Selyutin, Oleg,Dwyer, Michael P.,Nair, Anilkumar G.,Mazzola, Robert,Kim, Jae-Hun,Sha, Deyou,Yin, Jingjun,Ruck, Rebecca T.,Davies, Ian W.,Hu, Bin,Zhong, Bin,Hao, Jinglai,Ji, Tao,Zan, Shuai,Liu, Rong,Agrawal, Sony,Xia, Ellen,Curry, Stephanie,McMonagle, Patricia,Bystol, Karin,Lahser, Frederick,Carr, Donna,Rokosz, Laura,Ingravallo, Paul,Chen, Shiying,Feng, Kung-I,Cartwright, Mark,Asante-Appiah, Ernest,Kozlowski, Joseph A.
, p. 290 - 306 (2017/04/26)
We describe the research that led to the discovery of compound 40 (ruzasvir, MK-8408), a pan-genotypic HCV nonstructural protein 5A (NS5A) inhibitor with a "flat" GT1 mutant profile. This NS5A inhibitor contains a unique tetracyclic indole core while maintaining the imidazole-proline-valine Moc motifs of our previous NS5A inhibitors. Compound 40 is currently in early clinical trials and is under evaluation as part of an all-oral DAA regimen for the treatment of chronic HCV infection.
THIAZOLYL-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES
-
Page/Page column 40; 41, (2014/08/06)
The present invention relates to novel Thiazolyl-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A', R2R3, R4 and R5 are as defined herein. The present
